ADAM8蛋白在肝细胞癌的表达及其临床意义  

Expression of ADAM8 in hepatocellular carcinoma and its clinical significance

作　　者：张云[1] 胡本顺[3] 谈永飞[1] 葛志军[2] 蒋超[1] 张淼[1] 于晓天[1] 鱼海峰[1] 

机构地区：[1]江苏大学附属宜兴医院普外科,宜兴214200 [2]江苏大学附属宜兴医院重症医学科,宜兴214200 [3]江苏省江原医院普外科

出　　处：《中华肝胆外科杂志》2013年第2期116-119,共4页Chinese Journal of Hepatobiliary Surgery

摘　　要：目的探讨ADAM8在肝细胞癌患者的表达及其与病理因素和预后的关系。方法采用免疫组化法检测ADAM8在105例肝细胞癌组织的表达。应用酶联免疫吸附试验（ELIsA）检测126例肝细胞癌患者、50例肝硬化患者和50例健康体检者血清ADAM8蛋白的表达水平。分析血清ADAM8表达与患者预后的关系。结果免疫组化研究结果显示ADAM8蛋白表达与患者性别和年龄无明显相关性，但ADAM8蛋白的表达水平与肿瘤的大小、肿瘤病理类型、AFP水平和临床分期密切相关。肝细胞癌患者的血清ADAM8水平明显高于肝硬化患者和健康体检者。血清高表达ADAM8蛋白患者的5年生存率明显低于低表达患者（P〈0．001）。多因素分析显示，ADAM8的表达是影响患者预后的独立危险因素。结论ADAM8在肝细胞癌患者的表达与肿瘤的大小、病理类型、AFP水平、临床分期和预后密切相关。检测ADAM8表达水平对判断肝细胞癌的预后具有一定的参考价值。Objective To investigate the expression of ADAM8 in patients with hepatocellular carcinoma （HCC） and its clinical significance. Methods The protein expression of ADAM8 in HCC tissues was analyzed using immunohistochemical analysis. Serum levels of ADAM8 were measured by ELISA in 126 patients with HCC, 50 patients with liver cirrhosis （LC） and 50 healthy individuals. The relationship between patients＇ pathological features and serum ADAM8 level was analyzed. Results Immunohistochemical analysis showed that ADAM8 expression was associated closely with serum AFP elevation, tumor size, histological differentiation, and tumor stage. The ELISA assay showed that the serum levels of ADAM8 in the HCC were significantly higher than those in LC and healthy groups. Kaplan Meier survival analysis showed that high expression of serum ADAM8 exhibi- ted a significant correlation with poor prognosis for HCC patients. Multivariate analysis revealed that serum ADAM8 expression is an independent prognostic parameter for the overall survival rate of HCC patients. Conclusion ADAM8 expression was closely associated with tumor size, serum AFP eleva- tion, tumor differentiation, tumor stage and prognosis in hepatocellular carcinoma. Therefore, ADAM8 expression may serve as a biomarker for predicting the prognosis of patients in hepatocellular carcinoma.

关 键 词：解聚素和金属蛋白酶 ADAM8 肝癌 预后 

分 类 号：R735.7[医药卫生—肿瘤]